Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis

Opis bibliograficzny
Główni autorzy:	Sousos, N, Buck, G, Rodriguez-Meira, A, Norfo, R, Hamblin, A, Pezzella, F, Davies, J, Hublitz, P, Psaila, B, Mead, AJ
Format:	Journal article
Język:	English
Wydane:	Wolters Kluwer Health 2020

Podobne zapisy

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
od: Nikolaos Sousos, i wsp.
Wydane: (2020-06-01)

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
Wydane: (2021-05-01)

In utero origin of myelofibrosis presenting in adult monozygotic twins
od: Sousos, N, i wsp.
Wydane: (2022)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
od: Claire Harrison
Wydane: (2015-04-01)

Chronic Lymphocytic Leukemia and Myelofibrosis
od: Fares Darawshy, i wsp.
Wydane: (2018-01-01)

Treatment and management of myelofibrosis in the era of JAK inhibitors
od: Keohane C, i wsp.
Wydane: (2013-08-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
od: Andrew T. Kuykendall, i wsp.
Wydane: (2021-08-01)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
od: Reilly, J, i wsp.
Wydane: (2014)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
od: Keohane C, i wsp.
Wydane: (2013-10-01)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
od: Reilly, J, i wsp.
Wydane: (2014)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
od: Jui‐Che Chen, i wsp.
Wydane: (2022-02-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
od: M. V. Barabanshchikova, i wsp.
Wydane: (2016-03-01)

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis
od: Ristić Slobodan, i wsp.
Wydane: (2015-01-01)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
od: Douglas Tremblay, i wsp.
Wydane: (2023-06-01)

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
od: Louka, E, i wsp.
Wydane: (2021)

Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets
od: Psaila, B, i wsp.
Wydane: (2020)

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
od: Jay Y. Spiegel, i wsp.
Wydane: (2017-09-01)

Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
od: Fuping Wang, i wsp.
Wydane: (2024-12-01)

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
od: V. Pullarkat, i wsp.
Wydane: (2022-06-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
od: Prithviraj Bose, i wsp.
Wydane: (2020-08-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
od: Ayalew Tefferi, i wsp.
Wydane: (2023-03-01)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
od: Marshall A. Lichtman
Wydane: (2022-03-01)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
od: Naveen Pemmaraju, i wsp.
Wydane: (2022-11-01)

Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing
od: Rodriguez-Meira, A, i wsp.
Wydane: (2019)

Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis
od: Ke Chen, i wsp.
Wydane: (2024-08-01)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
od: Derek W. Brown, i wsp.
Wydane: (2022-09-01)

Acute massive myelofibrosis with acutelymphoblastic leukemia
od: Namık Özbek, i wsp.
Wydane: (2009-12-01)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
od: Francesco Angotzi, i wsp.
Wydane: (2022-02-01)

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis
od: Li, R, i wsp.
Wydane: (2024)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
od: Psaila, B, i wsp.
Wydane: (2017)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
od: Christopher Gerard Mullen, i wsp.
Wydane: (2022-11-01)

Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
od: Ayesha Gul, i wsp.
Wydane: (2022-06-01)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
od: Martina Barone, i wsp.
Wydane: (2020-01-01)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
od: Marte Karen Brattås, i wsp.
Wydane: (2018-11-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
od: O'Sullivan, JM, i wsp.
Wydane: (2023)

CLINICAL AND PATHOMORPHOLOGICAL EXAMINATION OF MYELOFIBROSIS IN CHRONIC MYELOID LEUKEMIA
od: T. Yu. Dolgikh, i wsp.
Wydane: (2016-02-01)

PATHOMORPHOLOGICAL ANALYSIS OF TREPANOBIOPTATES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA: ASSESSMENT OF THE PROGNOSTIC VALUE OF MYELOFIBROSIS WHEN COMPARED WITH CLINICAL DATA
od: T. Y. Dolgikh, i wsp.
Wydane: (2019-02-01)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
od: Michael Gulrajani, i wsp.
Wydane: (2023-08-01)

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
od: John O. Mascarenhas, i wsp.
Wydane: (2017-02-01)

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
od: Chowdhury, O, i wsp.
Wydane: (2020)